Royal Bank Of Canada Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $1.67 Million - $1.76 Million	-11,539 Reduced 45.61%	13,758 $2.08 Million
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $1.24 Million - $2.18 Million	-14,934 Reduced 37.12%	25,297 $3.69 Million
Q1 2022 May 16, 2022	SELL	$110.08 - $142.92 $117,565 - $152,638	-1,068 Reduced 2.59%	40,231 $4.77 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $2.46 Million - $3.66 Million	24,666 Added 148.3%	41,299 $5.69 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $1.07 Million - $1.51 Million	-10,841 Reduced 39.46%	16,633 $2.31 Million
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $1.81 Million - $2.89 Million	27,474 New	27,474 $2.67 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.